Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects
1College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828,
2Gyeongnam Biohealth Research Center, Gyeongnam Branch Institute, Korea Institute of Toxicology, Jinju 52834,
3College of Pharmacy, Kangwon National University, Chuncheon 24341,
4College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea
Tel: +82-55-772-2423, Fax: +82-55-772-2429
Received: December 28, 2021; Revised: February 1, 2022; Accepted: February 9, 2022; Published online: March 10, 2022.
© The Korean Society of Applied Pharmacology. All rights reserved.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/
) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.